MX2025015193A - Derivados policiclicos que contienen dihidropirimidina-2,4(1h,3h)-diona y sus composiciones farmaceuticas, metodos de preparacion y usos - Google Patents
Derivados policiclicos que contienen dihidropirimidina-2,4(1h,3h)-diona y sus composiciones farmaceuticas, metodos de preparacion y usosInfo
- Publication number
- MX2025015193A MX2025015193A MX2025015193A MX2025015193A MX2025015193A MX 2025015193 A MX2025015193 A MX 2025015193A MX 2025015193 A MX2025015193 A MX 2025015193A MX 2025015193 A MX2025015193 A MX 2025015193A MX 2025015193 A MX2025015193 A MX 2025015193A
- Authority
- MX
- Mexico
- Prior art keywords
- dihydropyrimidine
- dione
- preparation
- containing polycyclic
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023100520 | 2023-06-15 | ||
| PCT/CN2024/099076 WO2024255810A1 (fr) | 2023-06-15 | 2024-06-13 | Dérivés polycycliques contenant de la dihydropyrimidine-2, 4 (1h, 3h)-dione et composition pharmaceutique associée, leur procédé de préparation et leur utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025015193A true MX2025015193A (es) | 2026-02-03 |
Family
ID=93851373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025015193A MX2025015193A (es) | 2023-06-15 | 2025-12-15 | Derivados policiclicos que contienen dihidropirimidina-2,4(1h,3h)-diona y sus composiciones farmaceuticas, metodos de preparacion y usos |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4727940A1 (fr) |
| KR (1) | KR20260022448A (fr) |
| CN (1) | CN121794269A (fr) |
| AU (1) | AU2024302642A1 (fr) |
| IL (1) | IL325349A (fr) |
| MX (1) | MX2025015193A (fr) |
| WO (2) | WO2024255810A1 (fr) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021053555A1 (fr) * | 2019-09-16 | 2021-03-25 | Novartis Ag | Agents de dégradation de colle et leurs procédés d'utilisation |
| PH12022551482A1 (en) * | 2019-12-18 | 2023-11-29 | Novartis Ag | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN116940571A (zh) * | 2021-03-15 | 2023-10-24 | 诺华股份有限公司 | 苯并异噁唑衍生物及其用途 |
| PY2217419A (es) * | 2021-03-15 | 2022-09-27 | Novartis Ag | Derivados de pirazolopiridina y sus usos |
| CN116802182A (zh) * | 2021-03-15 | 2023-09-22 | 诺华股份有限公司 | 吡唑并吡啶衍生物及其用途 |
| WO2022195355A1 (fr) * | 2021-03-15 | 2022-09-22 | Novartis Ag | Dérivés de benzisoxazole et leurs utilisations |
| CN117203216A (zh) * | 2021-06-25 | 2023-12-08 | 和径医药科技(上海)有限公司 | 蛋白抑制剂或降解剂、包含其的药物组合物及医药上的用途 |
| US20240368121A1 (en) * | 2021-08-20 | 2024-11-07 | Biotheryx, Inc. | Estrogen receptor degraders, pharmaceutical compositions thereof, and their therapeutic applications |
-
2024
- 2024-06-13 WO PCT/CN2024/099076 patent/WO2024255810A1/fr not_active Ceased
- 2024-06-13 AU AU2024302642A patent/AU2024302642A1/en active Pending
- 2024-06-13 EP EP24822758.9A patent/EP4727940A1/fr active Pending
- 2024-06-13 CN CN202480040029.4A patent/CN121794269A/zh active Pending
- 2024-06-13 KR KR1020267001182A patent/KR20260022448A/ko active Pending
-
2025
- 2025-06-05 WO PCT/CN2025/099373 patent/WO2025256460A1/fr active Pending
- 2025-12-15 MX MX2025015193A patent/MX2025015193A/es unknown
- 2025-12-15 IL IL325349A patent/IL325349A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4727940A1 (fr) | 2026-04-22 |
| CN121794269A (zh) | 2026-04-03 |
| AU2024302642A1 (en) | 2026-02-05 |
| WO2025256460A1 (fr) | 2025-12-18 |
| KR20260022448A (ko) | 2026-02-19 |
| WO2024255810A1 (fr) | 2024-12-19 |
| IL325349A (en) | 2026-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220152A1 (ar) | مشتقات 3-(5- ميثوكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخداماتها | |
| ZA202403388B (en) | Small molecules for treatement of cancer | |
| JOP20220179A1 (ar) | N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها | |
| PH12022550611A1 (en) | Brd9 bifunctional degraders and their methods of use | |
| EA200600076A1 (ru) | Композиции и способы увеличения активности теломеразы | |
| EP4442241A3 (fr) | Remplacement du rétinol dans le traitement de la peau | |
| UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
| BRPI0517567A (pt) | composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto | |
| ZA202211464B (en) | Tetrahydroisoquinoline compounds as nrf2 activators | |
| ZA202307290B (en) | Pyrazolopyridine derivatives and uses thereof | |
| MY207469A (en) | Therapeutic compounds | |
| MA53427B1 (fr) | Inhibiteurs de l'arginase et leurs méthodes d'utilisation | |
| ZA202211465B (en) | Tetrahydroisoquinoline compounds as nrf2 activators | |
| WO2025019819A3 (fr) | Agents de dégradation de protéine à petites molécules de mutant de kras g12d | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| ATE192923T1 (de) | Verwendung von boswelliasäure zur behandlung von hirntumoren | |
| PH12021552133A1 (en) | Aromatic derivatives, preparation methods, and medical uses thereof | |
| MX2025015193A (es) | Derivados policiclicos que contienen dihidropirimidina-2,4(1h,3h)-diona y sus composiciones farmaceuticas, metodos de preparacion y usos | |
| MX2025005154A (es) | Formulaciones orales compactables de ibutamoren. | |
| PH12020551493A1 (en) | Triazacyclododecansulfonamide (``tcd``)-based protein secretion inhibitors | |
| WO2024231881A3 (fr) | Formes polymorphes et formulations de leriglitazone | |
| WO2024073328A3 (fr) | Procédés de traitement du cancer et compositions associées | |
| IL154775A0 (en) | 21-hydroxy-6, 19-oxidoprogesterone (21oh-6, 19op) analogues, their preparation and use | |
| WO2022104088A3 (fr) | Méthode de traitement d'une maladie amyloïdogénique | |
| MX2025010543A (es) | Composiciones que comprenden 5-metoxi-2-aminoindan para el tratamiento de la depresion |